Legacy Wealth Asset Management, LLC Halozyme Therapeutics, Inc. Transaction History
Legacy Wealth Asset Management, LLC
- $340 Million
- Q3 2025
A detailed history of Legacy Wealth Asset Management, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Legacy Wealth Asset Management, LLC holds 3,630 shares of HALO stock, worth $254,208. This represents 0.08% of its overall portfolio holdings.
Number of Shares
3,630
Previous 4,955
26.74%
Holding current value
$254,208
Previous $257,000
3.5%
% of portfolio
0.08%
Previous 0.08%
Shares
4 transactions
Others Institutions Holding HALO
# of Institutions
666Shares Held
128MCall Options Held
626KPut Options Held
455K-
Black Rock Inc. New York, NY17.6MShares$1.23 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.6MShares$814 Million0.01% of portfolio
-
State Street Corp Boston, MA5.02MShares$351 Million0.01% of portfolio
-
Arrowstreet Capital, Limited Partnership Boston, MA3.29MShares$230 Million0.16% of portfolio
-
Invesco Ltd. Atlanta, GA3.25MShares$227 Million0.04% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $9.75B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...